GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Industry body PhRMA also hit back at the Democrat’s pricing plan, saying in a statement that it “would end the current market-based system that has made the US the

House Democrats finally pass landmark drug pricing bill

Alzheimer's, ALS and cancer, without hope for the treatments and cures they need," said Stephen Ubl, CEO of PhRMA.

Democrats reveal pricing plan with 250-drug hit list

Industry body PhRMA said in a statement that the Democrat plan “would end the current market-based system that has made the US the global leader in developing innovative, life-saving

White House unveils plans to reimport medicines from Canada

PhRMA's Stephen Ubl. “The administration’s importation scheme is far too dangerous for American patients. ... PhRMA had been in support of proposals to ban the current system of rebate payments from pharma to PBMs, but this plan was recently

Who's calling the shots in European healthcare?

PME: A number of stakeholders say that EFPIA’s opposition to the SPC Waiver was disproportionate, and influenced by US pharma lobby groups such as PhRMA.

Streamlining clinical trials – why better data use is key

According to a PhrMA survey, industry invested $71.4bn in R&D in 2017, up from $29.8bn in 2001.

The handover: Pfizer reshapes itself for a new era

For the US market, this would formerly have been seen as an outrageous idea, and US pharma CEOs and industry lobby group PhRMA have opposed the move.

Drug R&D

Country report: The healthcare market in South Korea

However, the Pharmaceutical Research and Manufacturers of America (PhRMA) said in a statement in February 2012 that it was 'highly concerned' that provisions regarding the reimbursement of innovative drugs and countering

Interview: Jane Griffiths, Janssen EMEA

Griffiths is a member of the EFPIA Board, chairwoman of the PhRMA Europe Committee, co-chairwoman of the EFPIA Executive Committee, a steering committee member of the J&J Women's

New faces at JPA Health Communications, GCI Health and HRW

Recently, she managed accounts for PhRMA and Johnson &Johnson. HRW. Joining HRW's leadership team is Sue Rees, who has been appointed as global director.

Weekly industry appointments

Fonteyne’s history has also seen him sit on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA) industry association and has held various roles with Boehringer Ingelheim, Abbot

IFPMA appoints Fumie Griego as assistant director general

international health policy at Pharmaceutical Research and Manufacturers of America (PhRMA).

Astellas names Linda Friedman as EVP, general counsel

She is chair of the board of director at the iBIO Institute, and a member of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Healthcare Business Women's Association

Astellas adds to US comms team

The appointment comes just days after Astellas announced the appointment of PhRMA's Karl Uhlendorf as communications and advocacy director.

Should diversity in clinical trials be mandatory?

Making diversity mandatory is a “no-brainer” for him and he emphasised that while, in November 2020, FDA (and subsequently PhRMA in November 2020) have released guidance in the United States,

3 reasons why clinical trials will thrive in 2021

However, with the FDA and PhRMA releasing new guidance it is likely we will start to see real change.

New from the PhRMA: Diversity in clinical trials principles summarised

In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. ... To address this, PhRMA will be committed to:. a.Enhancing education and diversity among clinical investigators.

COUCH Health

In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. ... The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021.